PP_1170x120_10-25-21

Ridgeback Biotherapeutics

Merck and Ridgeback announce U.S. government to purchase 1.4 million additional courses of molnupiravir

Merck and Ridgeback announce U.S. government to purchase 1.4 million additional courses of molnupiravir

KENILWORTH, N.J. — Merck and Ridgeback Biotherapeutics announced Tuesday that the United States government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA),

Merck reports experimental COVID-19 pill cut deaths, hospitalizations in half when given early

Merck reports experimental COVID-19 pill cut deaths, hospitalizations in half when given early

KENILWORTH, N.J. —Merck announced Friday that it has developed an experimental COVID-19 pill that is said to reduced hospitalizations and deaths by half in people recently infected with the coronavirus. The company said that it would soon ask health officials in the U.S. and around the world to authorize its use. If cleared, Merck’s drug